Novo Nordisk is bigger than Denmark's economy — but the prime minister isn't worried about another Nokia
Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s ...
Denmark’s Premier Brushes Off Risk as Novo Outgrows Economy
Danish Prime Minister Mette Frederiksen said she’s “extremely proud” of the country’s corporate champions, and rejected ...
EconoTimes13h
Denmark’s PM Downplays Concerns Over Novo Nordisk’s Dominance Amid Economic Growth Surge
Denmarks Prime Minister, Mette Frederiksen, rejected concerns over the economic risks posed by Novo Nordisks rapid growth.
Novo says Ozempic to be eligible for US price negotiations in less than a year
(Reuters) - Novo Nordisk (NYSE: NVO )'s blockbuster diabetes drug Ozempic will be eligible for U.S. government's price ...
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing ...
Novo Nordisk A/S - share repurchase programme
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
Novo Loses Second Place in Danish Revenue Rankings to DSV
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
Copenhagen Post4d
Novo Holdings: “The challenges we face are too large for any single institution”
Marcus Remmers, a partner of the Planetary Health Investments team of Novo Holdings, the controlling shareholder of Novo ...
New Hampshire Union Leader1d
Novo’s Wegovy price tag on stroke prevention is higher in US
Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...
The Star7d
Novo loses second place in Danish revenue rankings
COPENHAGEN: Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments. However, the pharma giant just got a bump down on the list of the ...